RYBREVANT
-
RYBREVANT® Plus LAZCLUZE® Overcomes Osimertinib Resistance in First-Line EGFR-Mutated NSCLC
Johnson & Johnson’s Phase 3 MARIPOSA study reveals that first-line RYBREVANT® plus LAZCLUZE® significantly reduces EGFR- and MET-driven resistance in EGFR-mutated NSCLC compared to osimertinib. The combination demonstrates a lower incidence of MET amplification and EGFR mutations, potentially transforming disease biology. This chemo-free regimen has shown an overall survival benefit exceeding four years. These findings, presented at WCLC 2025, support the combination’s approval in multiple markets.
